NEW YORK (GenomeWeb News) – Celera Genomics and Applied Biosystems are looking to sell some California real estate.
Celera Genomics is seeking to sell a 44,000-square-foot facility in South San Francisco that had been used for its scuttled small-molecule drug-discovery efforts, the company said in a Securities and Exchange Commission filing yesterday.
The facility sits on land parent Applera leases under a long-term ground lease, the company said. This space, together with three leased facilities totaling 108,000 square feet, was part of Celera’s small-molecule drug-discovery and –development business.
As of the end of June, Celera discontinued all internal research and development efforts in these programs and had vacated “substantially all” of the space in these facilities. Two of the leases expired in August and one will run out in December.
Meantime ABI is looking to lease “several” facilities in an undisclosed city, and to sell a 15-acre plot of land it owns in Vacaville, the company said in the SEC filing.
ABI has also finished constructing the shell of a building that sits on an 80-acre parcel it owns in Pleasanton. This space is around 164,000 square feet and ABI said it “intends” to make improvements to the space as needed for itself or “possibly the operations of our other businesses.”
ABI also said it may build additional R&D, manufacturing, administrative, or “other facilities” on this land, up to a maximum of approximately 700,000 additional square feet, “as may be required for the future growth of our businesses.”